- Home
- VNDA vs TVRD Comparison
VNDA vs TVRD Comparison
Compare VNDA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- TVRD
- Stock Information
- Founded
- VNDA 2002
- TVRD 2017
- Country
- VNDA United States
- TVRD United States
- Employees
- VNDA N/A
- TVRD N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- TVRD Health Care
- Exchange
- VNDA Nasdaq
- TVRD Nasdaq
- Market Cap
- VNDA 249.4M
- TVRD 246.5M
- IPO Year
- VNDA 2006
- TVRD N/A
- Fundamental
- Price
- VNDA $4.51
- TVRD $33.88
- Analyst Decision
- VNDA Strong Buy
- TVRD Strong Buy
- Analyst Count
- VNDA 2
- TVRD 5
- Target Price
- VNDA $16.50
- TVRD $59.20
- AVG Volume (30 Days)
- VNDA 404.6K
- TVRD 21.2K
- Earning Date
- VNDA 11-05-2025
- TVRD 08-14-2025
- Dividend Yield
- VNDA N/A
- TVRD N/A
- EPS Growth
- VNDA N/A
- TVRD N/A
- EPS
- VNDA N/A
- TVRD N/A
- Revenue
- VNDA $203,467,000.00
- TVRD N/A
- Revenue This Year
- VNDA $15.45
- TVRD N/A
- Revenue Next Year
- VNDA $37.82
- TVRD N/A
- P/E Ratio
- VNDA N/A
- TVRD N/A
- Revenue Growth
- VNDA 11.78
- TVRD N/A
- 52 Week Low
- VNDA $3.81
- TVRD $8.13
- 52 Week High
- VNDA $5.55
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- VNDA 46.90
- TVRD 66.16
- Support Level
- VNDA $4.54
- TVRD $29.33
- Resistance Level
- VNDA $4.64
- TVRD $31.88
- Average True Range (ATR)
- VNDA 0.15
- TVRD 2.09
- MACD
- VNDA -0.01
- TVRD 0.49
- Stochastic Oscillator
- VNDA 8.89
- TVRD 69.21
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.